What to know about uterine fibroids
HIGH POINT, N.C. (WGHP) — Uterine fibroids cause pain for some women.
Others don't even know they have them, but more than 70% of women will experience uterine fibroids during their lifetime.
This is Uterine Fibroid Awareness Week. In the FOX8 House Call, Dr. April Miller, an OB/GYN at Atrium Health Wake Forest Baptist, explains what uterine fibroids are and how they're treated.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
Owens & Minor and Rotech Healthcare Mutually Agree to Terminate Previously Announced Acquisition
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) today announced it has mutually agreed with Rotech Healthcare Holdings Inc. to terminate the previously announced acquisition. Under the terms of the merger agreement, Owens & Minor has paid $80 million to Rotech Healthcare. Owens & Minor will also redeem the $1 billion of notes issued in April 2025, which include a special mandatory redemption provision in accordance with their terms, and terminate the incremental term loan commitments and senior unsecured bridge loan commitments provided by our lenders which would have been utilized to consummate the acquisition. 'For many months, our teammates, along with the Rotech team, have worked tirelessly in cooperation with the Federal Trade Commission to close this transaction, and while we believe there would have been ample benefits to patients, payors, and providers by adding Rotech to our Patient Direct business, the path to obtain regulatory clearance for this merger proved unviable in terms of time, expense, and opportunity,' said Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor. 'We are confident in our strategy and will continue to focus our efforts on growing our Patient Direct business while remaining committed to strengthening our balance sheet through the use of improved cash flow generation for deleveraging. The home-based care market is a dynamic, growing market, and we are extremely well positioned to help those with chronic conditions get the care and service they need and deserve. Also, we continue to work with a number of interested parties around the potential sale of our Products and Healthcare Services business, and, in the meantime, we will continue to actively work to strengthen that business and tap into its significant upside'. 'I want to thank our teammates, partners and everyone at Rotech for their effort and cooperation over the last several months, and we look forward to a bright future with many years of profitable growth,' Pesicka concluded. About Owens & Minor Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit or follow us on LinkedIn and Instagram. * Registered Trademark or Trademark of O&M Halyard or its affiliates. This press release shall not constitute an offer to buy the notes issued in April 2025, which will be conducted pursuant to a special mandatory redemption in accordance with the terms of the notes.
Yahoo
40 minutes ago
- Yahoo
Applied Medical Technology, Inc. Unveils Redesigned Mobile App Aligned with Recent Website Refresh
BRECKSVILLE, Ohio., June 10, 2025 /PRNewswire/ -- Applied Medical Technology, Inc. (AMT), a leader in innovative medical devices, is proud to announce the launch of its redesigned mobile application, AMT ONE Source®. This strategic update follows a successful website redesign completed late 2024, ensuring that both platforms now offer a cohesive, user-friendly digital experience. Enhancing User Experience Across PlatformsThe redesigned mobile app mirrors the modern, intuitive design language introduced during the website refresh. With a renewed focus on user experience and engagement, the mobile platform now features streamlined interfaces and updated information. "In today's fast-paced healthcare environment, it is essential that our digital platforms are not only reliable but also easy to navigate and visually appealing," said Bill Bentley, National Sales Manager. "Created with our youngest patients in mind, the redesign was thoughtfully developed to be more engaging, age-appropriate, and easy to navigate—helping children and their families feel more supported and empowered throughout their healthcare journey." Key Features and Benefits Unified Design Aesthetic: The mobile app adopts the clean, modern design previously launched on the website, providing a consistent look and feel across all digital touchpoints. Richer Content Experience: The app now features an expanded content database, providing a broader range of resources and information to support users with timely, relevant, and easy-to-access content. Improved Performance: The redesigned app features enhanced performance, with a new backend architecture that allows for faster content updates, easier maintenance, and more frequent improvements to keep the experience fresh and relevant. AMT partnered with Cleveland-Ohio based software company, Stream 9, on the redesign. Their strong track record in software design and development brought deep technical expertise and a strategic approach. "We're fortunate in our business to develop custom software projects for businesses of all kinds; but it's especially rewarding to work on a project that will deliver such a direct benefit to patients and their caregivers. AMT brought a clear vision to the table, and we worked closely together to translate that into a modern, scalable, and user-friendly digital experience," shared Kirk Miesle, Founder of Stream 9. The AMT ONE Source® app is available now on the App Store and Google Play. About AMT: Applied Medical Technology, Inc. (AMT) is a global leader in enteral and surgical devices committed to improving lives through innovation. For 40 years, AMT has bridged the gap between medical technology and patient needs, collaborating with healthcare professionals and users to develop high-quality, life-enhancing solutions. Our holistic approach prioritizes the well-being of the whole person, not just the device they use. View original content to download multimedia: SOURCE Applied Medical Technology, Inc.
Yahoo
2 hours ago
- Yahoo
Perimeter Medical Imaging AI to Present at the Life Sciences Virtual Investor Forum on June 12th
TORONTO and DALLAS, June 10, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that its CEO, Adrian Mendes, will present an update on the Company's business at the Life Sciences Virtual Investor Forum on Thursday, June 12, 2025 at 12:30 p.m. Eastern Time. A live stream of the presentation will be available here and on the Investors section of Perimeter's website, where it will also be archived for approximately 90 days. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that was recently evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT, the expected benefits of Perimeter's updated version of its ImgAssist AI, and Perimeter's expectations regarding the outcomes of the clinical trial and future submission to the FDA are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2023, which is available on Perimeter's SEDAR+ profile at and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. CONTACTS: Stephen KilmerInvestor RelationsDirect: 647-872-4849Email: skilmer@ Adrian MendesChief Executive OfficerToll-free: 888-988-7465 (PINK)Email: investors@ View original content to download multimedia: SOURCE Perimeter Medical Imaging AI Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
